Timothy C. Atkins

Timothy C. Atkins is a partner in the Life Sciences group at Goodwin. He joined the firm in 2023. Tim advises startups and venture capital-backed business as well as publicly traded, global companies in the pharmaceutical, biotechnology, and medical device sectors. His work includes acquisition, protection, commercialization, and disposition of intellectual property assets as well as acting as outside general counsel for startup and emerging growth companies in the life sciences handling common formation, counseling of founders, private financings, and mergers and acquisitions.

Tim has extensive experience with life science-focused licensing, collaboration, joint development, joint venture transactions, and asset acquisition and dispositions transactions and with the panoply of commercial transactions pursued by life sciences companies including sponsored research, contract, manufacturing, supply, distribution, and clinical trial agreements.

Representative matters include:

• Represented Century Therapeutics (NASDAQ: IPSC) in a research collaboration and license agreement for the development and commercialization up to four induced pluripotent stem cell derived, engineered natural killer cell and / or T cell programs for hematologic malignancies and solid tumors. Century received a $100 million upfront fee as well as a $50 million equity investment*
• Represented Code Bio in a collaboration and option agreement with Takeda to leverage Code Bio’s proprietary targeted 3DNA® non-viral genetic medicine delivery platform to design and develop gene therapies for rare disease indications. Code Bio is eligible to receive future development and commercial milestone payments plus tiered royalties with a potential total deal value over the course of the partnership of up to $2 billion if milestones for all four programs are achieved*
• Represented iECURE in a research, option and license agreement with the University of Pennsylvania (Penn) to develop next-generation lipid nanoparticles (LNP) for liver gene editing applications*
• Represented Botanix Pharmaceuticals Limited (ASX:BOT) on its purchase of a NDA ready therapy for the treatment of axillary hyperhidrosis from Fresh Tracks Therapeutics*
• Represented Avalo Therepeutics in an in-license of a biospecimen repository, related phenotypic data and related patents owned by major pediatric medical center for use in the field of rare and orphan diseases along with a companion Sponsored Research Agreement*
• Represented Avalo Therapeutics in an in-license of a monoclonal antibody and related intellectual property from a multibillion-dollar Japanese licensor*
• Represented Avalo Therapeutics in an in-license of a novel BTLA-agonist fusion protein from Sanford Burnham Prebys*
• Served as outside general counsel to Neuronetics both before and after its initial public offering on the NASDAQ Global Market*
• Represented Neuronetics in a distribution agreement for its transcranial magnetic stimulation devices with a world-class distributor in Japan*
• Represented Apnimed Inc. in in-licenses of technology applicable to its sleep apnea therapeutics*
• Represented Churchill Pharmcaeutics and iCeutica Inc. in the buyout of a license agreement by Sun Pharmaceuticals*
• Represented Hikma Pharmaceuticals in its acquisition of Custopharm for $425 million*
• Represented an inventor in the sale of a royalty stream to DRI Healthcare*
• Represented a venture-backed commercial-stage medical device company on the initial acquisition of its launch product line and subsequent business development activities*
• Represented a Finnish pharmaceutical company in an out-license of US rights for a pharmaceutical compound to a NASDAQ-listed company*
• Represented a NASDAQ-listed company in the acquisition of molecular diagnostic assets for thyroid and pancreatic cancers*
• Represented a publicly traded biotechnology and diagnostics company in the global commercialization of a patented technology platform for use in various diagnostic applications including structuring and negotiating research, development and supply agreements for instrumentation, assays and related supplies and the cross-licensing of various technologies*
• Advised on an out-licensing of a cardiovascular pharmaceutical compound candidate and related intellectual property by a global pharmaceutical company to a venture capital-backed pharmaceutical company*
• Advised on an out-licensing of a peptide directed to the treatment of diabetes by a venture capital-backed company to a global pharmaceutical company*
• Counseled on worldwide out-licensing of an approved product used in the palliative treatment of prostate cancer*
• Represented a specialty pharmaceutical company in connection with all aspects of its commercialization activities including out-licensing, in-licensing of a drug candidate and various vendor contracts including supply and quality agreements*
• Represented a publicly traded pharmaceutical company in a product development transaction, international licensing arrangements and strategic alliances*
• Represented a biotechnology company in a collaboration arrangement and related licensing arrangements with a government-funded research institution*
• Represented multiple companies in sponsored research, option, license, and clinical trial agreements with universities and affiliated health systems*
• Advised on a $50 million Series B financing of a development stage pharmaceutical company*
• Represented a venture capital-backed company in a license and collaboration transaction involving its drug discovery platform*
• Advised on an acquisition of an off-the-market pharmaceutical product line including all related assets*
• Represented multiple pharmaceutical companies in connection with pre-clinical and clinical development activities including services agreements with CROs and supporting vendors, clinical study agreements, laboratory services agreements, and CRADAs*
• Represented a database company in the licensing of its absorption, distribution, metabolism and excretion database to pharmaceutical companies*
• Advised a French software company on the formation of its US affiliate company and licensing of drug discovery software to US pharmaceutical companies*
• Counseled a pharmaceutical company in the acquisition of mission critical research software*
• Represented selling shareholders in $200 million leveraged buyout by management*
• Represented a private equity fund in an acquisition of a call center business and aircraft charter services businesses*
• Negotiated and documented senior debt, mezzanine debt and preferred equity investments*
• Advised various companies and individuals in connection with mergers and acquisitions, including asset purchase and stock purchase transactions, cash-out mergers and stock-for-stock mergers*
• Counseled a US software developer on the establishment of domestic and international reseller and value-added reseller relationships*
• Advised on a meeting planning and travel service company on the licensing of software and the provision of related services to Fortune 500 companies*
• Advised an automotive trade group on copyright and other issues surrounding the development of a Web site*
• Counseled software developers and software users on the use of source code escrows*
• Counseled a university and research group regarding joint authorship issues in a regionally administered survey*
• Advised a provider of electronic data interchange software on software licensing, domestic value-added reseller relationships, and the development of a web-based EDI transaction clearinghouse*
• Represented several major universities in the structuring and negotiation of technology transfer transactions including sponsored research agreements, materials transfer, and evaluation agreements, option agreements, license agreements, and equity-based technology transfers*
• Represented a university and research group regarding joint authorship issues in a regionally administered survey*
• Represented a university in connection with licensing content for use on a health-oriented website*
• Represented a university in contract negotiations for the licensing of a distance learning/e-education platform*
• Advised on multiple development, license, service and sale agreements governing the development, use, supply and commercialization of high technology assets such as software, databases, and hardware*

*Denotes experience prior to joining Goodwin.